Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia

Itaru Kataoka, Katsuji Shinagawa, Yoshihiko Shiro, Shinichiro Okamoto, Reiko Watanabe, Takehiko Mori, Daisuke Ito, Mine Harada

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We report a chronic myelogenous leukemia (CML) patient in chronic phase (CP) who developed multiple sclerosis (MS) in association with interferon-alpha (IFN-α) administration. In our patient, recombinant IFN-α2b therapy induced hematologically complete and cytogenetically major partial response for CML first, and sequential central nervous system dysfunction evolved, which subsided shortly after the cessation of its administration. Restarting IFN-α therapy by changing to a natural type of IFN-α resulted in rapid exacerbation of MS. The patient's neurological symptoms progressed gradually, but partial hematologic response persisted without any IFN-α derivatives or anti-cancer agents until a matched unrelated donor transplant procedure was performed. Myeloablative therapy led to lasting stable state of MS and finally to complete cytogenetic remission of CML. This patient's presenting clinical course and laboratory data suggest that both exertion of anti-leukemic activity and autoimmune process of MS might be mediated by mutual mechanisms, such as enhancement of specific cellular immunity induced by IFN-α.

Original languageEnglish
Pages (from-to)149-153
Number of pages5
JournalAmerican Journal of Hematology
Volume70
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferon-alpha
Multiple Sclerosis
interferon alfa-2b
Therapeutics
Unrelated Donors
Cellular Immunity
Cytogenetics
Central Nervous System
Transplants
Neoplasms

Keywords

  • Allogeneic bone marrow transplantation
  • Autoimmune disease
  • Cellular immunity
  • Chronic myelogenous leukemia
  • Interferon-alpha
  • Multiple sclerosis

ASJC Scopus subject areas

  • Hematology

Cite this

Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia. / Kataoka, Itaru; Shinagawa, Katsuji; Shiro, Yoshihiko; Okamoto, Shinichiro; Watanabe, Reiko; Mori, Takehiko; Ito, Daisuke; Harada, Mine.

In: American Journal of Hematology, Vol. 70, No. 2, 2002, p. 149-153.

Research output: Contribution to journalArticle

Kataoka, Itaru ; Shinagawa, Katsuji ; Shiro, Yoshihiko ; Okamoto, Shinichiro ; Watanabe, Reiko ; Mori, Takehiko ; Ito, Daisuke ; Harada, Mine. / Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia. In: American Journal of Hematology. 2002 ; Vol. 70, No. 2. pp. 149-153.
@article{bab0e6e75fa2430c923154ca6f6c4da7,
title = "Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia",
abstract = "We report a chronic myelogenous leukemia (CML) patient in chronic phase (CP) who developed multiple sclerosis (MS) in association with interferon-alpha (IFN-α) administration. In our patient, recombinant IFN-α2b therapy induced hematologically complete and cytogenetically major partial response for CML first, and sequential central nervous system dysfunction evolved, which subsided shortly after the cessation of its administration. Restarting IFN-α therapy by changing to a natural type of IFN-α resulted in rapid exacerbation of MS. The patient's neurological symptoms progressed gradually, but partial hematologic response persisted without any IFN-α derivatives or anti-cancer agents until a matched unrelated donor transplant procedure was performed. Myeloablative therapy led to lasting stable state of MS and finally to complete cytogenetic remission of CML. This patient's presenting clinical course and laboratory data suggest that both exertion of anti-leukemic activity and autoimmune process of MS might be mediated by mutual mechanisms, such as enhancement of specific cellular immunity induced by IFN-α.",
keywords = "Allogeneic bone marrow transplantation, Autoimmune disease, Cellular immunity, Chronic myelogenous leukemia, Interferon-alpha, Multiple sclerosis",
author = "Itaru Kataoka and Katsuji Shinagawa and Yoshihiko Shiro and Shinichiro Okamoto and Reiko Watanabe and Takehiko Mori and Daisuke Ito and Mine Harada",
year = "2002",
doi = "10.1002/ajh.10090",
language = "English",
volume = "70",
pages = "149--153",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia

AU - Kataoka, Itaru

AU - Shinagawa, Katsuji

AU - Shiro, Yoshihiko

AU - Okamoto, Shinichiro

AU - Watanabe, Reiko

AU - Mori, Takehiko

AU - Ito, Daisuke

AU - Harada, Mine

PY - 2002

Y1 - 2002

N2 - We report a chronic myelogenous leukemia (CML) patient in chronic phase (CP) who developed multiple sclerosis (MS) in association with interferon-alpha (IFN-α) administration. In our patient, recombinant IFN-α2b therapy induced hematologically complete and cytogenetically major partial response for CML first, and sequential central nervous system dysfunction evolved, which subsided shortly after the cessation of its administration. Restarting IFN-α therapy by changing to a natural type of IFN-α resulted in rapid exacerbation of MS. The patient's neurological symptoms progressed gradually, but partial hematologic response persisted without any IFN-α derivatives or anti-cancer agents until a matched unrelated donor transplant procedure was performed. Myeloablative therapy led to lasting stable state of MS and finally to complete cytogenetic remission of CML. This patient's presenting clinical course and laboratory data suggest that both exertion of anti-leukemic activity and autoimmune process of MS might be mediated by mutual mechanisms, such as enhancement of specific cellular immunity induced by IFN-α.

AB - We report a chronic myelogenous leukemia (CML) patient in chronic phase (CP) who developed multiple sclerosis (MS) in association with interferon-alpha (IFN-α) administration. In our patient, recombinant IFN-α2b therapy induced hematologically complete and cytogenetically major partial response for CML first, and sequential central nervous system dysfunction evolved, which subsided shortly after the cessation of its administration. Restarting IFN-α therapy by changing to a natural type of IFN-α resulted in rapid exacerbation of MS. The patient's neurological symptoms progressed gradually, but partial hematologic response persisted without any IFN-α derivatives or anti-cancer agents until a matched unrelated donor transplant procedure was performed. Myeloablative therapy led to lasting stable state of MS and finally to complete cytogenetic remission of CML. This patient's presenting clinical course and laboratory data suggest that both exertion of anti-leukemic activity and autoimmune process of MS might be mediated by mutual mechanisms, such as enhancement of specific cellular immunity induced by IFN-α.

KW - Allogeneic bone marrow transplantation

KW - Autoimmune disease

KW - Cellular immunity

KW - Chronic myelogenous leukemia

KW - Interferon-alpha

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0036105496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036105496&partnerID=8YFLogxK

U2 - 10.1002/ajh.10090

DO - 10.1002/ajh.10090

M3 - Article

C2 - 12111789

AN - SCOPUS:0036105496

VL - 70

SP - 149

EP - 153

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -